Drug resistance arises when disease causing organisms or cells adapt so that medicines that once worked become less effective. It is a major challenge in treating infections and cancers.

In bacteria, resistance often develops through genetic mutations or by acquiring resistance genes from other microbes. These changes can alter drug targets, pump drugs out of the cell, or break down the drug molecule. Overuse and misuse of antibiotics in medicine, agriculture and livestock amplify this process by creating strong selective pressure. Resistant strains such as MRSA and multidrug resistant tuberculosis illustrate how this can undermine routine treatments and increase mortality.

Viruses also evolve resistance, particularly when they replicate rapidly under drug pressure. For example, HIV and hepatitis viruses can accumulate mutations that reduce the binding or activity of antiviral drugs. Combination therapies that use several drugs at once make it harder for the virus to evolve resistance to all agents simultaneously.

Cancer cells show similar evolutionary dynamics. Within a tumor, some cells may carry or acquire mutations that allow them to survive chemotherapy or targeted drugs. These resistant clones can eventually dominate, leading to relapse. Mechanisms include changes in drug targets, activation of alternate signaling pathways, enhanced DNA repair and increased drug efflux.

Researchers are responding with strategies such as drug combinations, cycling or adaptive dosing, development of new antibiotics and antivirals, inhibitors of efflux pumps, and approaches that target resistance mechanisms themselves. Surveillance, rapid diagnostics and stewardship programs are also vital. Without effective action, drug resistance threatens to erode the gains of modern medicine and make common infections and cancers far harder to treat.